Nuveen
KROS icon

Nuveen’s Keros Therapeutics KROS Stock Holding History

Nuveen’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.65M Sell
247,756
-14,319
-5% -$160K ﹤0.01% 2440
2026
Q1 		$2.89M Buy
262,075
+198,978
+315% +$3.07M ﹤0.01% 2121
2025
Q4 		$1.28M Sell
63,097
-12,758
-17% -$224K ﹤0.01% 2489
2025
Q3 		$1.2M Hold
75,855
– – ﹤0.01% 2538
2025
Q2 		$1.01M Sell
75,855
-3,871,600
-98% -$52.3M ﹤0.01% 2600
2025
Q1 		$94.5M Buy
3,947,455
+3,867,970
+4,866% +$44.9M 0.03% 406
2024
Q4 		$1.26M Sell
79,485
-181,863
-70% -$9.45M ﹤0.01% 2604
2024
Q3 		$15.2M Buy
261,348
+153,568
+142% +$7.58M ﹤0.01% 1363
2024
Q2 		$4.93M Buy
107,780
+6,541
+6% +$351K ﹤0.01% 1962
2024
Q1 		$6.7M Buy
101,239
+25,643
+34% +$1.52M ﹤0.01% 1826
2023
Q4 		$3.01M Buy
75,596
+4,578
+6% +$144K ﹤0.01% 2224
2023
Q3 		$2.26M Buy
71,018
+19,359
+37% +$723K ﹤0.01% 2248
2023
Q2 		$2.08M Sell
51,659
-15,510
-23% -$680K ﹤0.01% 2331
2023
Q1 		$2.87M Buy
67,169
+1,830
+3% +$92.4K ﹤0.01% 2186
2022
Q4 		$3.14M Buy
65,339
+646
+1% +$30.2K ﹤0.01% 2173
2022
Q3 		$2.43M Buy
64,693
+1,753
+3% +$60.8K ﹤0.01% 2295
2022
Q2 		$1.74M Buy
62,940
+2,445
+4% +$107K ﹤0.01% 2505
2022
Q1 		$3.08M Sell
60,495
-2,982
-5% -$153K ﹤0.01% 2303
2021
Q4 		$2.97M Sell
63,477
-4,625
-7% -$231K ﹤0.01% 2372
2021
Q3 		$2.09M Sell
68,102
-47,363
-41% -$1.69M ﹤0.01% 2653
2021
Q2 		$4.9M Sell
115,465
-8,822
-7% -$478K ﹤0.01% 2257
2021
Q1 		$7.65M Buy
124,287
+29,275
+31% +$1.85M ﹤0.01% 1941
2020
Q4 		$6.7M Buy
95,012
+67,928
+251% +$4.28M ﹤0.01% 1920
2020
Q3 		$1.04M Buy
27,084
+114
+0.4% +$4.52K ﹤0.01% 2670
2020
Q2 		$1.01M Buy
+26,970
New +$831K ﹤0.01% 2619

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Nuveen's KROS Position: Q2 2026 in Review

Nuveen reduced its Keros Therapeutics (KROS) stake by 5.5% in Q2 2026, selling an estimated $160K and leaving 247,756 shares worth $2.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2440.

Nuveen first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $94.5M in Q1 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Nuveen held 247,756 shares of Keros Therapeutics worth $2.65M as of Q2 2026.
  • Nuveen sold 14,319 Keros Therapeutics shares in Q2 2026, an estimated $160K.
  • Keros Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2440 holding.
  • Nuveen first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Nuveen's Keros Therapeutics position peaked at $94.5M in Q1 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.